Focused on sustaining operational performance in near-term: Jubilant Life

Drug firm Jubilant Life Sciences is focused on sustaining its operational and financial performance in the near-term in the current scenario unleashed by the COVID-19 pandemic, according to its latest annual report.

The company posted a total revenue from operations of Rs 9,154.4 crore in FY20, up 0.5 per cent year-on-year, with international revenue of Rs 7,124 crore contributing 78 per cent to the total revenue, its annual report for fiscal year 2019-20 said.

"The company, in the near-term, is focused on sustaining its operational and financial performance in the current uncertain scenario unleashed by the COVID-19 pandemic, with medium-term focus at ensuring sustainable growth across our various businesses," the company's chairman Shyam S Bhartia and co-chairman and managing director Hari S Bhartia said in their message to shareholders.

To tide over the COVID-19 pandemic led crisis, the company in the near-term is deferring its major capex plans, without sacrificing growth, until the business environment stabilises, they said.

The company is focused on generating healthy operating cash flows to further reduce debt levels, the message said.

"We continue to stay focused on our strategy of being closer to the customer and of further strengthening our leadership position in defined businesses," it added.

The company's diversified businesses are segmented in three major verticals namely pharmaceuticals, life science ingredients and drug discovery and development solutions, the report said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel